Ultragenyx Pharmaceutical (LTS:0LIF) Cyclically Adjusted Book per Share: $10.80 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LIF Ultragenyx Pharmaceutical Inc LTS:0LIF
65 GF Score
Price $25.01
GF Value $46.14
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share?

Ultragenyx Pharmaceutical LTS:0LIF -0.97% 65 Cyclically Adjusted Book per Share is $10.80 as of Mar. 2026. GuruFocus rates LTS:0LIF with a GF Score™ of 65/100 and a GF Value™ of $46.14 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2026 was $-2.400. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.80 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ultragenyx Pharmaceutical's average Cyclically Adjusted Book Growth Rate was -11.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Ultragenyx Pharmaceutical was -3.20% per year. The lowest was -3.20% per year. And the median was -3.20% per year.

As of today (2026-07-31), Ultragenyx Pharmaceutical's current stock price is $25.01. Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $10.80. Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is 2.32.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 5.58. The lowest was 1.75. And the median was 3.28.


Ultragenyx Pharmaceutical  (LTS:0LIF) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=25.01/10.80
=2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ultragenyx Pharmaceutical was 5.58. The lowest was 1.75. And the median was 3.28.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Related Terms


Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 12.19 12.40 12.15 10.85

Ultragenyx Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.18 12.07 11.63 10.85 10.80

LTS:0LIF vs ATAI, QURE, KOD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PB Ratio falls into.


LTS:0LIF
65GF Score
Ultragenyx Pharmaceutical Inc LTS:0LIF
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ultragenyx Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-2.4/330.2130*330.2130
=-2.400

Current CPI (Mar. 2026) = 330.2130.

Ultragenyx Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201606 11.369 241.018 15.576
201609 11.382 241.428 15.568
201612 11.493 241.432 15.719
201703 11.555 243.801 15.651
201706 10.122 244.955 13.645
201709 8.604 246.819 11.511
201712 8.682 246.524 11.629
201803 14.571 249.554 19.281
201806 14.047 251.989 18.408
201809 13.112 252.439 17.152
201812 11.972 251.233 15.736
201903 15.474 254.202 20.101
201906 14.216 256.143 18.327
201909 12.593 256.759 16.196
201912 11.303 256.974 14.524
202003 10.240 258.115 13.100
202006 11.514 257.797 14.748
202009 10.954 260.280 13.897
202012 17.276 260.474 21.901
202103 15.638 264.877 19.495
202106 14.346 271.696 17.436
202109 13.738 274.310 16.538
202112 13.304 278.802 15.757
202203 11.411 287.504 13.106
202206 9.685 296.311 10.793
202209 6.690 296.808 7.443
202212 5.021 296.797 5.586
202303 3.120 301.836 3.413
202306 1.805 305.109 1.954
202309 0.439 307.789 0.471
202312 3.346 306.746 3.602
202403 1.688 312.332 1.785
202406 4.693 314.175 4.933
202409 3.757 315.301 3.935
202412 2.757 315.605 2.885
202503 1.536 319.799 1.586
202506 1.570 322.561 1.607
202509 0.095 324.800 0.097
202512 -0.829 324.054 -0.845
202603 -2.400 330.213 -2.400

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $10.80 mean?
Ultragenyx Pharmaceutical (LTS:0LIF) has a Cyclically Adjusted Book per Share of $10.80 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share too high?
Ultragenyx Pharmaceutical's current Cyclically Adjusted Book per Share is $10.80. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share compare to ATAI and QURE?
Ultragenyx Pharmaceutical's Cyclically Adjusted Book per Share of $10.80 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Cyclically Adjusted Book per Share is $10.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (LTS:0LIF) is currently considered Possible Value Trap. The stock's GF Value™ is $46.14, compared to a current price of $25.01 — trading 45.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is $10.80. Ultragenyx Pharmaceutical's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (LTS:0LIF), the current Cyclically Adjusted Book per Share is $10.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (LTS:0LIF) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of $25.01 is trading 45.8% below its estimated GF Value™ of $46.14. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for LTS:0LIF:

  • Cyclically Adjusted Book per Share: $10.80
  • GF Value™: $46.14 vs. price of $25.01 (45.8% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the LTS:0LIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
65GF Score

Get the complete analysis for LTS:0LIF

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.01
Price
$46.14
GF Value